Lazard Asset Management LLC raised its stake in Co-Diagnostics, Inc. (NASDAQ:CODX – Get Rating) by 101.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 20,095 shares of the company’s stock after buying an additional 10,099 shares during the quarter. Lazard Asset Management LLC owned 0.06% of Co-Diagnostics worth $112,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the stock. Walleye Trading LLC increased its stake in Co-Diagnostics by 148.2% in the 2nd quarter. Walleye Trading LLC now owns 33,822 shares of the company’s stock valued at $190,000 after buying an additional 20,193 shares during the period. Bank of America Corp DE increased its stake in Co-Diagnostics by 218.8% in the 1st quarter. Bank of America Corp DE now owns 7,220 shares of the company’s stock valued at $45,000 after buying an additional 4,955 shares during the period. Quantbot Technologies LP bought a new stake in Co-Diagnostics in the first quarter worth approximately $46,000. Royal Bank of Canada grew its position in Co-Diagnostics by 4.8% in the first quarter. Royal Bank of Canada now owns 79,882 shares of the company’s stock worth $493,000 after acquiring an additional 3,654 shares in the last quarter. Finally, State Street Corp grew its position in Co-Diagnostics by 15.6% in the first quarter. State Street Corp now owns 96,547 shares of the company’s stock worth $597,000 after acquiring an additional 13,063 shares in the last quarter. Institutional investors and hedge funds own 22.56% of the company’s stock.
Co-Diagnostics Trading Up 3.3 %
NASDAQ:CODX opened at $3.47 on Wednesday. Co-Diagnostics, Inc. has a 1 year low of $2.76 and a 1 year high of $10.90. The firm’s fifty day simple moving average is $3.31 and its 200 day simple moving average is $4.43. The firm has a market capitalization of $107.29 million, a PE ratio of 7.38 and a beta of -1.04.
Wall Street Analysts Forecast Growth
Several research firms have commented on CODX. Sidoti downgraded shares of Co-Diagnostics from a “buy” rating to a “neutral” rating and set a $5.00 target price for the company. in a research report on Friday, August 12th. HC Wainwright decreased their target price on shares of Co-Diagnostics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, November 14th.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.
- Get a free copy of the StockNews.com research report on Co-Diagnostics (CODX)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.